MJA 2001; 175: 294-296
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- Revision of statement on publication ethics by the International
Correspondence:
- 1.
- Henderson L. More AMCs finding growth from reform.Centerwatch 2000; 7(6): 1, 10-13.
- 2.
- Kowalczyk L. Harvard, other medical schools aim to give drug firmsfaster pace for trials. Boston Globe 2000; Jul 28, C4.
- 3.
- Mathieu MP. Parexel's pharmaceutical R&D statisticalsourcebook, 1998 edition. Waltham, Mass: Parexel InternationalCorporation, 1999.
- 4.
- Rennie D. Thyroid storm. JAMA 1997; 277: 1238-1243.
- 5.
- Kahn JO, Cherng DW, Mayer K, et al, for the 806 Investigator Team.Evaluation of HIV-1 immunogen, an immunologic modifier,administered to patients infected with HIV having 300 to 549 x106/LCD4 cell counts. A randomized controlled trial. JAMA 2000;284: 2193-2202.
- 6.
- Blumenthal D, Campbell EG, Anderson MS, et al. Withholdingresearch results in academic life science: evidence from a nationalsurvey of faculty. JAMA 1997; 277: 1224-1228.
Online responses are no longer available. Please refer to our instructions for authors page for more information.